haihongyuan.com
海量文库 文档专家
全站搜索:
您现在的位置:首页 > 初中教育 > 科学科学

肝脂素对人和大鼠肝癌作用的研究

发布时间:2014-01-14 11:57:10  

Efficacy and Mechanisms of Anticancer Remedy Heplipin in Primary Liver Cancer of Human and Rat.
Hayashi K*, Ambaga M#, Lu JP&, and Hurelbaatar L# *Okayama University, 700, Japan #Oncology Center, Mongolia &Shanghai Med.Univ, 200032 China

Materials and Methods (1)
Table 1 Staging of 47 Patients (43~73 yr ) Groups Sex Stage Total M F III IV Heplipin 26 7 13 20 33 Chemo. 8 2 4 6 10 Control 3 1 2 2 4 Total 37 10 19 28 47

Materials and Methods (2)
Table 2. Grouping and treatment of the rats Grouping (N) Treatment Week 1-13 Week 13-22
A (8) Maize+DAB+Heplipin A B (8) Maize+DAB+Heplipin A S (8) Maize+DAB C(7) Maize Common Food + Heplipin A Common Food +Heplipin B Common Food Common Food

Results
Table 3 Improvement of symptoms
Symptoms
Weight loss

Before
17

After Improvement %
10 58.0

Appetite loss Nausea/vomiting General fatigue Fever Stool Change

17 13 12 4 16

10 10 6 4 10

58.0 84.6 50.0 100 62.5

Results
Table 3 Improvement of symptoms(2)
Symptoms Hepatic area pain on Pain on the chest Dyspnea* Skin dryness Jaundice** Ascites and edema Before After 13 9 8 11 3 20 10 9 3 4 0 12 Improve (%) 84.6 100 37.5 36.6 0 60.0

Table 4. Side effects of treatment

Introduction Heplipin Chemotherapy
0 I II III~IV 7 2 5 1 5 2 5 3 2 4 3 2 3 4 3

Toxicity Grade 0 Digestive system Nausea/vomiting 33 Diarrhea 33 Stomatitis 33 Marrow suppression RBC 33 WBC 33 PI 33

Table 4. Side effects of treatment(2) Heplipin Chemotherapy
Toxicity Grade 0
Liver function Kidney function Skin lesion Alopecia Eruption Dryness Edema 33 33 33 33 33 33

0 I II III~IV
6 3 5 3 3 4 1 1 2 4 4 3 3 4 1 1 1 1

Table 5 Hematological findings
Heplipin Group (N=33)

Examinations

Before

After

RBC count (1012/L) 3.8± 0.2 4.4± 0.1 Hb (g/L) 106.6 ±10.1 113.3± 9.9 WBC counts (109/L) 4.0 ± 0.5 4.9 ± 0.6 WBC classification (%) Granulocyte (seg) 60.5 ± 0.1 52.0 ± 0.1 Lymphocyte 32.8 ± 1.8 40.4 ± l.9 Monocyte 6.9 ± 0.2 8.2 ± l.l Erythrocyte 22.8 ± l.0 20.0 ± 0.5

Table 5 Hematological findings(2)
Examinations Chemotherapy Group (N=10) Before After 3.7±0.2 109.1 ± 9.0 4.1 ± 0.4 62.1 ± l.6 31.3 ± l.8 5.8 ± 0.5 22.6 ± l.0 3.0± 0.3 100 ± 10.2 2.9 ± 0.8. 8.2 ± 2.8 14.2 ± 2.8 3.0 ± 0.8 25.0 ± l.0

RBC count (1012/L) Hb (g/L) WBC counts (109/L) WBC classification (%) Granulocyte (seg) Lymphocyte Monocyte Erythrocyte

Table 6 Biochemical Changes
Examinations Heplipin Group (N=33) Before After

Serum protein (g/L) 69.9 ± 2.5 77.9± 5.1 Serum albumin (mmol/L) 42. l ± 5.1 43.1± 4.5 Serum globulin (mmol/L) 3.2 ± 0.1 3.8 ±0.1 Bilirubin (mg/dl) 1.2± 0.l 0.9 ±0.2 Thymol reaction (U) 10 ± l.4 4.4 ±l. 3 Alt (U) 83.3 ±15.3 73.9 ±1.5 Ast (U) 69.5 ± 14.2 44.3± 6.7

Table 6 Table 6 Biochemical Biochemical Changes Changes
Examinations Heplipin Group (N=33) Before After Serum protein (g/L) 70.0±2.3 62 ±1.8 Scrum albumin (mmol/L) 43.0±4.2 40 ±2.5 Serum globulin (mmol/L) 3.2 ±0.3 2.2±0.4 Bilirubin (mg/dl) l.3 ±0.2 l.4±0.2 Thymol reaction (U) 10 ± l.2 13 ±l.8 Alt

(U) 80 ±16.1 120±13 Ast (U) 68 ±16 88 ± 6.2 Blood urea (mol/L) 4.8±1.4 7.4±1.5 Creatinine (umol/L) 78 ±20 96 ±20

Table 7 Changes of tumor size in Heplipin Group Tumor Size Before After Suppression (%)

Longitudinal d (cm) 6.2 ± 0.8 5.0 ± 0.6* 60% Cross d (cm) 60% Square (cm2) 60% 5.8 ± 0.7 4.6 ± 0.5* 38.7± 8.5 25 ± 5.6

Table 8 Clinical assessments on tumor suppression
Effects CR+PR Improvement

Groups

CR PR MR NC PD

(%)
33

(%)
22 (66.6)

Heplipin 0 10 11 10 2

(n=33)
Chemo (n=10) Control 0 0 0 0 4 0 0 ( 0.0) 0 2 5 2 1 21 2 (20.0)

Table 9. Results of the rat groups (mean±SD)
Group (N) Body Weight Liver Weight Spleen Weight Liver /Body

A (7)
B (7)

266.67 ±10.33 9.34 ±0.84
280.00 ±20.61 8.04 ±0.51

0.91±0.32
0.82±0.26

3.51±0.37
2.88±0.23

S (6)
C (7)

285.00 ±14.83 15.20 ±4.64
278.33 ±13.66 7.54 ±0.35

1.20±0.27
0.80±0.10

5.34±1.62
2.78±0.15

Conclusion (Human Case)
Heplipin
Decreasing tumor size CR+PR Symptoms Improved Hepatic function Hemopoiesis 80 % Improved Improved 10% Worsen Worsen 66.6 %

Chemotherapy
20%

Renal functions

Improved

Worsen

Conclusion (Rat Experiment)
Group Heplipin A and B v.s. Group Saline

Less Inflammatory cell infiltration, fibrosis
Reduction of liver injury Less Dysplastic & Cancer foci Liver cancer prevention/treatment Obvious Kupffer’s cell proliferation another anticancer mechanism


网站首页网站地图 站长统计
All rights reserved Powered by 海文库
copyright ©right 2010-2011。
文档资料库内容来自网络,如有侵犯请联系客服。zhit326@126.com